中药协同131I治疗Graves病的临床研究

探讨中药石麦清液协同131I治疗Graves病(GD)的疗效及给药方法.GD患者100例随机分为A组:131I治疗,B组:131I 石麦清液治疗,服131I后7d服石麦清液20mL每天3次共40d.以治疗前和治疗后30d、90d测定血清FT3、FT4和TSH并选择8种症状,采用Kupperman四级评分评估.结果表明B组临床症状提前改善,安全渡过131I治疗一月后出现的FT3、FT4反跳性升高,A组30d后临床症状重于治疗前,FT3、FT4高于治疗前.B组90d临床症状显著改善,FT3、FT4和TSH测值正常,A组临床症状改善,但FT3、FT4低于正常,TSH高于正常.30d后B组安全渡过高危期,90d治疗后,减轻甲状腺功能减退症发病率疗效优于A组.石麦清液无毒性、安全和可在临床推广应用.

Clinical Observation of Associated Treatment for Graves' Disease with Traditional Chinese Medicine and 131I

To investigate the method and curative effect of associated treatment for Graves Disease(GD) with traditional Chinese medicine and 131I.100 patients with GD were randomly divided into two groups,the patients in group A was only given 131I treatment and the patients in group B was given traditional Chinese medicine(Shimaiqing Fluid,3 times of 20 mL per day for 40 days) after 7 days of 131I treatment.The serum FT3,FT4 and TSH were measured before and 30 and 90 days after treatment.8 cardinal symptoms were selected and Kupperman 4-grade grading method was used to assess the remission of the disease.The Results showed that the symptoms of patients in group B were improved ahead of time,and pass through the FT3 and FT4 rebound elevation period safely after one month of 131I treatment.The symptoms of patients in group A after 30 days treatment were more serious than that of before treatment,the levels of serum FT3 and FT4 were both higer than those of before treatment.The symptoms of patients in group B after 90 days treatment were improved significantly,and the levels of serum FT3,FT4 and TSH were in normal value.The clinical symptoms of patients in group A were improved,but the levels of serum FT3 and FT4 were lower and TSH was higher than normal value.The curative effect in group B was better than that in group A,the patients passed through the high risk period safely after 30 days treatment,and the hypothyroidism rate was decreased after 90 days treatment.The Shimaiqing Fluid is a nontoxic and safe medicine,and it may be widely used in clinical treatment for patients with GD.